National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 58289-58290 [2021-22954]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Notices
Oncology Application
The VAR2CSA immunogens bind to
oncofetal CSA, a putative therapeutic
target for multiple cancers, including
NSCLC, breast, bladder and 40–50% of
all pediatric solid tumors. Oncofetal
CSA is only expressed solely in the
placenta, except in several cancerous
tissues, making it an ideal target for
targeted therapeutics such as
immunogens that are cross linked to
cytotoxic agents.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Placental malaria vaccine
• CSA-binding proteins for cancer
therapeutics
Competitive Advantages:
• Strain-transcending immunogens for
vaccination
• Improved immunogen production
through expression of key protein
regions
Development Stage:
• Immunogens successfully tested in
a small animal model
jspears on DSK121TN23PROD with NOTICES1
Inventors: Dr. Niraj Tolia and Dr. Rui
Ma, both of NIAID.
Publications: Ma, R. et al., ‘‘Structural
basis for placental malaria mediated by
Plasmodium falciparum VAR2CSA’’,
Nat Microbiol 6, 380–391, 2021.
Intellectual Property: HHS Reference
No. E–021–2021–0–US–01—U.S.
Provisional Application No. 63/115,729,
filed November 19, 2020.
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the invention. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483;
peter.tung@nih.gov.
Dated: October 15, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–22918 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:35 Oct 20, 2021
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Limited Interaction Targeted
Epidemiology (LITE–2): To Advance HIV
Prevention (UG3/UH3 Clinical Trial
Optional).
Date: November 17, 2021.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Kristina S. Wickham,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20852, 301–761–5390,
kristina.wickham@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 15, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22953 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
58289
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Institutional
Training Grants I.
Date: November 2, 2021.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3400 Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ashley Fortress, Ph.D.,
Designated Federal Official, Division of
Extramural Activities, National Eye Institute,
National Institutes of Health, 6700B
Rockledge Drive, Suite 3400, Bethesda, MD
20892, (301) 451–2020, ashley.fortress@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: October 15, 2021.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22919 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
E:\FR\FM\21OCN1.SGM
21OCN1
58290
Federal Register / Vol. 86, No. 201 / Thursday, October 21, 2021 / Notices
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement
(U01); NIAID SBIR Phase II Clinical Trial
Implementation Cooperative Agreement
(U44); Investigator Initiated Extended
Clinical Trial (R01).
Date: October 28–29, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mohammed S. Aiyegbo,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20852, (301) 761–7106,
mohammed.aiyegbo@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 15, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–22954 Filed 10–20–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Senior Executive Service Performance
Review Boards
Office of the Secretary,
Department of Homeland Security.
ACTION: Correction notice.
AGENCY:
This notice announces the
appointment of members of the Senior
Executive Service (SES) Performance
Review Boards (PRBs) for the
Department of Homeland Security
(DHS). The purpose of the PRBs is to
make recommendations to the
appointing authority (i.e., Component
head) on the performance of senior
executives (career, noncareer, and
limited appointees), including
recommendation on performance
ratings, performance-based pay
adjustments, and performance awards.
The PRBs will also make
recommendations on the performance of
Transportation Security Executive
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:35 Oct 20, 2021
Jkt 256001
Service, Senior Level, and Scientific and
Professional employees. To make its
recommendations, the PRBs will review
performance appraisals, initial summary
ratings, any response by the employee,
and any higher-level official’s findings.
DATES: This Notice is effective as of
October 21, 2021.
FOR FURTHER INFORMATION CONTACT: Greg
Ruocco, Director, Executive Resources,
Office of the Chief Human Capital
Officer, greg.ruocco@hq.dhs.gov, (202)
897–8470.
SUPPLEMENTARY INFORMATION: In
accordance with 5 U.S.C. 4314(c) and 5
CFR 430.311, each agency must
establish one or more PRBs to make
recommendations to the appointing
authority (i.e., Component head) on the
performance of its senior executives.
Each PRB must consist of three or more
members. More than one-half of the
membership of a PRB must be SES
career appointees when reviewing
appraisals and recommending
performance-based pay adjustments or
performance awards for career
appointees. Composition of the specific
PRBs will be determined on an ad hoc
basis from among the individuals listed
below:
List of Names (Alphabetical Order)
Adamcik, Carol A
Aguilar, Max
Alfonso-Royals, Angelica
Allen, Matthew C
Alles, Randolph D
Anderson, Sandra D
Antognoli, Anthony
Archambeault, Gregory J
Armstrong, Gloria R
Arratia, Juan
Baden, Mary
Bailey, Angela S
Baker, Jeremy D
Baker, Paul E
Barksdale-Perry, Nicole C
Baroukh, Nader
Barrera, Staci A
Barrett, Lawrence R
Beagles, James M
Berg, Peter B
Berger, Katrina W
Bernstein, Meira
Bhagowalia, Sanjeev
Bible, Daniel A
Bible, Kenneth
Blackwell, Juliana J
Blessey, Caroline
Bobich, Jeffrey M
Bonner, Bryan
Borkowski, Mark S
Boyd, John
Boyer, Stephen A
Bradshaw, Patricia S
Brane, Michelle
Braun, Jacob H
Brewer, Julie S
Bright, Andrea J
Brito, Roberto
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Brown, Alan S
Browne, Rene E
Brundage, William
Bryan, Michelle C
Bucholtz, Kathleen L
Bullock, Edna
Bunker, Michael D
Burgess, Kenneth
Burks, Atisha
Burns, Robert P
Burriesci, Kelli A
Bush, Thomas L
Bush, William B
Cagen, Steven W
Caggiano, Marshall L
Caine, Jeffrey
Cameron, Michael K
Campo, Brian
Canevari, Holly E
Canty, Rachel E
Cappello, Elizabeth A
Carnes, Alexandra
Carpio, Philip F
Carraway, Melvin J
Castro, Raul M
Chaleki, Thomas D
Cheatle, Kimberly A
Cheng, Wen-Ting
Clark, Alaina
Cleary Stannard, Jennifer S
Cline, Richard K
Cloe, David
Cofield, Valerie M
Cohen, John D
Collins, James L
Condon, John A
Cook, Charles
Coronado, Luis
Corrado, Janene M
Cotter, Daniel
Courey, Marc B
Courtney, Paul
Coven, Phyllis
Cox, Adam
Cox, Debra S
Cronen, Christopher M
Cross, Catherine C
Crumpacker, Jim H
Culliton-Gonzalez, Katherine
Cunningham, John D
Dainton, Albert J
Dargan, John L
Das, Sharmistha
Daskal, Jennifer
Davidson, Michael J
Davis, Michael P
Davis, Michael P
Dawson, Inga I
Decker, Thomas R
Dembling, Ross W
DeNayer, Larry C
Denton, David L
DeQuattro, Pat
Di Pietro, Joseph R
DiFalco, Frank J
Dipippa, Kathy L
Dobitsch, Stephanie M
Doran, Thomas J
Dornburg, Erica M
Dorr, Robert
Dragani, Nancy J
Dunbar, Susan C
Dupree, Lynn
Eaton, Joseph J
Ederheimer, Joshua A
Edwards, Benjamin R
E:\FR\FM\21OCN1.SGM
21OCN1
]]>Agencies
[Federal Register Volume 86, Number 201 (Thursday, October 21, 2021)]
[Notices]
[Pages 58289-58290]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-22954]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant
[[Page 58290]]
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
Cooperative Agreement (U01); NIAID SBIR Phase II Clinical Trial
Implementation Cooperative Agreement (U44); Investigator Initiated
Extended Clinical Trial (R01).
Date: October 28-29, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mohammed S. Aiyegbo, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20852, (301) 761-7106, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 15, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-22954 Filed 10-20-21; 8:45 am]
BILLING CODE 4140-01-P
